Paige, Perspectum forge AI-centered clinical trial alliance

By Emily Jarecki

- Last updated on GMT

(PM Images/iStock via Getty Images Plus)
(PM Images/iStock via Getty Images Plus)

Related tags Artificial intelligence Data management Liver Liver disease Pathology

The digital pathology firm and image-analysis software developer will partner on artificial intelligence based solutions to improve trial decision making.

Perspectum, a software developer focused on image analysis solutions, and digital pathology company Paige have announced a partnership. According to the two firms, their teams plan to work together to use artificial intelligence (AI) and quantitative tools to help enhance decision-making abilities in trials, and to empower pathologists.

“We are excited to partner with Paige and to work together to find better ways to improve the delivery of services and the quality of histology biomarkers in late-phase trials,”​ said Rajarshi Banerjee, CEO of Perspectum. “Paige’s mission to develop the next generation of computational technology that can translate into effective, personalized care for patients is a shared mission, and ​[Paige CEO] Leo Grady has built a wonderful team to address the digital transformation of pathology.”

This partnership will combine Perspectum’s digital pathology service and integrated repository platform for both non-invasive and histology datasets with Paige’s digital pathology software tools which include FullFocus, an FDA-cleared and CE-marked digital pathology viewing platform. This will enhance clinical trials by streamlining the operational workflow and allowing access to novel decision support tools for pathologists.

Ultimately these improvements will increase the robustness and reliability of trials and allow pharmaceutical sponsors to overcome the pitfalls and obstacles traditionally associated with pathology endpoints in clinical trials,” ​said Vidhya Kumar, vice president of business development for pharma solutions with Perspectum.

Focus on liver disease

Kumar said, “Liver disease is a major concern in the US, and Perspectum has developed non-invasive, imaging-based biomarkers as well as digital pathology tools to better characterize and understand these conditions. This partnership combines Perspectum’s experience in the management and delivery of biomarkers for liver disease clinical trials with Paige’s broader expertise in pathology.”

“Paige looks forward to contributing its expertise in computational pathology and collaborating with Perspectum to modernize pathology workflows in the clinical trial setting with the ultimate aim of improving the diagnosis and treatment of liver disease,”​ said Grady.

Related news

Related products

show more

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 10-Mar-2023 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

4 Warning Signs Your Research Site Is in Trouble

4 Warning Signs Your Research Site Is in Trouble

Elligo Health Research® | 10-Mar-2023 | Insight Guide

You want your clinical research practice to be a success for your business and your patients, but how can you tell if it’s in trouble? Read this article...

How Sponsors Reduce Chaos in Decentralized Trials

How Sponsors Reduce Chaos in Decentralized Trials

Florence Healthcare | 08-Mar-2023 | Insight Guide

89% of research sponsors currently use and expect to continue the use of decentralized technologies and methods, according to our state of the industry...

Standardizing data with NCI controlled terminology

Standardizing data with NCI controlled terminology

Formedix | 13-Feb-2023 | Technical / White Paper

The use of consistent terminology within and between studies is critical to enabling an efficient trial process. CDISC standards such as CDASH, SDTM, SEND...

Related suppliers

Follow us


View more